Brief: Tissue Repair Says FDA Clears Phase 3 Clinical Program For Drug Candidate TR-987
29/05/2023 02:21
May 29 (Reuters) - Tissue Repair Ltd TRP.AX :
* FDA CLEARS CO TO PROGRESS INTO PHASE 3 CLINICAL PROGRAM
FOR DRUG
CANDIDATE TR-987
Source text for Eikon: ID:nASXbymTtb
Further company coverage: TRP.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tissue Repair
See all newsBrief: Tissue Repair Resumes Direct Distribution Of TR Pro+ In Australia, New Zealand
Brief: Tissue Repair Posts FY Loss Attributable Of A$5.4 Million
Brief: Tissue Repair Says Formally Applied To ASX Requesting Its Removal From Official List Of ASX
Brief: Tissue Repair Signs A Multi-Year Distribution Agreement With Advanced Cosmeceuticals Pty
Australia's Tissue Repair rises to 3-month high on securing distributor for flagship product